{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T16:51:45Z","timestamp":1790787105715,"version":"4.1.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T00:00:00Z","timestamp":1770336000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T00:00:00Z","timestamp":1773100800000},"content-version":"vor","delay-in-days":32,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Ophthalmol"],"DOI":"10.1186\/s12886-026-04651-w","type":"journal-article","created":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T14:52:18Z","timestamp":1770389538000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Intravitreal faricimab in patients with refractory diabetic macular edema: 6-month fluid analysis using artificial intelligence"],"prefix":"10.1186","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-4066-8871","authenticated-orcid":false,"given":"Nicolas","family":"Owlya","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mickael","family":"Barbosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9522-7176","authenticated-orcid":false,"given":"Nicol\u00f2","family":"Bartolomeo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-3697-9121","authenticated-orcid":false,"given":"Yannic","family":"Pannatier-Schuetz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna Chiara","family":"Nascimbeni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5145-5126","authenticated-orcid":false,"given":"Daniela Gallo","family":"Castro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mamadou Path\u00e9","family":"Barry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6543-3400","authenticated-orcid":false,"given":"Aude","family":"Ambresin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,6]]},"reference":[{"key":"4651_CR1","doi-asserted-by":"publisher","first-page":"e1221","DOI":"10.1016\/S2214-109X(17)30393-5","volume":"5","author":"SR Flaxman","year":"2017","unstructured":"Flaxman SR, Bourne RRA, Resnikoff S, Ackland P, Braithwaite T, Cicinelli MV, et al. Global causes of blindness and distance vision impairment 1990\u20132020: a systematic review and meta-analysis. Lancet Glob Health. 2017;5:e1221\u201334. https:\/\/doi.org\/10.1016\/S2214-109X(17)30393-5.","journal-title":"Lancet Glob Health"},{"key":"4651_CR2","unstructured":"Guidelines on Diabetic Eye Care. The International Council of Ophthalmology Recommendations for Screening, Follow-up, Referral, and Treatment Based on Resource Settings - PubMed. https:\/\/pubmed.ncbi.nlm.nih.gov\/29776671\/. Accessed 9 Jan 2026."},{"key":"4651_CR3","doi-asserted-by":"publisher","first-page":"2399","DOI":"10.2337\/dc10-0493","volume":"33","author":"P Massin","year":"2010","unstructured":"Massin P, Bandello F, Garweg JG, Hansen LL, Harding SP, Larsen M, et al. Safety and efficacy of Ranibizumab in diabetic macular edema (RESOLVE Study): a 12-month, randomized, controlled, double-masked, multicenter phase II study. Diabetes Care. 2010;33:2399\u2013405. https:\/\/doi.org\/10.2337\/dc10-0493.","journal-title":"Diabetes Care"},{"key":"4651_CR4","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1016\/j.ophtha.2010.03.045","volume":"117","author":"M Michaelides","year":"2010","unstructured":"Michaelides M, Kaines A, Hamilton RD, Fraser-Bell S, Rajendram R, Quhill F, et al. A prospective randomized trial of intravitreal bevacizumab or laser therapy in the management of diabetic macular edema (BOLT study) 12-month data: report 2. Ophthalmology. 2010;117:1078\u2013e10862. https:\/\/doi.org\/10.1016\/j.ophtha.2010.03.045.","journal-title":"Ophthalmology"},{"key":"4651_CR5","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1016\/j.ophtha.2011.01.031","volume":"118","author":"P Mitchell","year":"2011","unstructured":"Mitchell P, Bandello F, Schmidt-Erfurth U, Lang GE, Massin P, Schlingemann RO, et al. The RESTORE study: Ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology. 2011;118:615\u201325. https:\/\/doi.org\/10.1016\/j.ophtha.2011.01.031.","journal-title":"Ophthalmology"},{"key":"4651_CR6","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1016\/j.ophtha.2011.12.039","volume":"119","author":"QD Nguyen","year":"2012","unstructured":"Nguyen QD, Brown DM, Marcus DM, Boyer DS, Patel S, Feiner L, et al. Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE. Ophthalmology. 2012;119:789\u2013801. https:\/\/doi.org\/10.1016\/j.ophtha.2011.12.039.","journal-title":"Ophthalmology"},{"key":"4651_CR7","doi-asserted-by":"publisher","first-page":"2044","DOI":"10.1016\/j.ophtha.2015.06.017","volume":"122","author":"DM Brown","year":"2015","unstructured":"Brown DM, Schmidt-Erfurth U, Do DV, Holz FG, Boyer DS, Midena E, et al. Intravitreal Aflibercept for diabetic macular edema: 100-Week results from the VISTA and VIVID studies. Ophthalmology. 2015;122:2044\u201352. https:\/\/doi.org\/10.1016\/j.ophtha.2015.06.017.","journal-title":"Ophthalmology"},{"key":"4651_CR8","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1016\/j.ophtha.2016.02.022","volume":"123","author":"JA Wells","year":"2016","unstructured":"Wells JA, Glassman AR, Ayala AR, Jampol LM, Bressler NM, Bressler SB, et al. Aflibercept, Bevacizumab, or Ranibizumab for diabetic macular edema: Two-Year results from a comparative effectiveness randomized clinical trial. Ophthalmology. 2016;123:1351\u20139. https:\/\/doi.org\/10.1016\/j.ophtha.2016.02.022.","journal-title":"Ophthalmology"},{"key":"4651_CR9","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.ajo.2022.01.004","volume":"238","author":"DM Brown","year":"2022","unstructured":"Brown DM, Emanuelli A, Bandello F, Barranco JJE, Figueira J, Souied E, et al. KESTREL and KITE: 52-Week results from two phase III pivotal trials of Brolucizumab for diabetic macular edema. Am J Ophthalmol. 2022;238:157\u201372. https:\/\/doi.org\/10.1016\/j.ajo.2022.01.004.","journal-title":"Am J Ophthalmol"},{"key":"4651_CR10","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.ajo.2023.07.012","volume":"260","author":"CC Wykoff","year":"2024","unstructured":"Wykoff CC, Garweg JG, Regillo C, Souied E, Wolf S, Dhoot DS, et al. KESTREL and KITE phase 3 studies: 100-Week results with Brolucizumab in patients with diabetic macular edema. Am J Ophthalmol. 2024;260:70\u201383. https:\/\/doi.org\/10.1016\/j.ajo.2023.07.012.","journal-title":"Am J Ophthalmol"},{"key":"4651_CR11","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.survophthal.2022.11.008","volume":"68","author":"OA Sorour","year":"2023","unstructured":"Sorour OA, Levine ES, Baumal CR, Elnahry AG, Braun P, Girgis J, et al. Persistent diabetic macular edema: Definition, incidence, biomarkers, and treatment methods. Surv Ophthalmol. 2023;68:147\u201374. https:\/\/doi.org\/10.1016\/j.survophthal.2022.11.008.","journal-title":"Surv Ophthalmol"},{"key":"4651_CR12","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1001\/jamaophthalmol.2017.6565","volume":"136","author":"NM Bressler","year":"2018","unstructured":"Bressler NM, Beaulieu WT, Glassman AR, Blinder KJ, Bressler SB, Jampol LM, et al. Persistent macular thickening following intravitreous Aflibercept, Bevacizumab, or Ranibizumab for Central-Involved diabetic macular edema with vision impairment: A secondary analysis of a randomized clinical trial. JAMA Ophthalmol. 2018;136:257\u201369. https:\/\/doi.org\/10.1001\/jamaophthalmol.2017.6565.","journal-title":"JAMA Ophthalmol"},{"key":"4651_CR13","doi-asserted-by":"publisher","first-page":"156","DOI":"10.4274\/tjo.56338","volume":"47","author":"B Nur\u00f6zler Tabakc\u0131","year":"2017","unstructured":"Nur\u00f6zler Tabakc\u0131 B, \u00dcnl\u00fc N. Corticosteroid treatment in diabetic macular edema. Turk J Ophthalmol. 2017;47:156\u201360. https:\/\/doi.org\/10.4274\/tjo.56338.","journal-title":"Turk J Ophthalmol"},{"key":"4651_CR14","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.2147\/DMSO.S214098","volume":"12","author":"KL Spooner","year":"2019","unstructured":"Spooner KL, Guinan G, Koller S, Hong T, Chang AA. Burden of treatment among patients undergoing intravitreal injections for diabetic macular oedema in Australia. Diabetes Metab Syndr Obes Targets Ther. 2019;12:1913\u201321. https:\/\/doi.org\/10.2147\/DMSO.S214098.","journal-title":"Diabetes Metab Syndr Obes Targets Ther"},{"key":"4651_CR15","doi-asserted-by":"publisher","first-page":"9424","DOI":"10.3390\/ijms23169424","volume":"23","author":"S Liberski","year":"2022","unstructured":"Liberski S, Wichrowska M, Koci\u0119cki J. Aflibercept versus faricimab in the treatment of neovascular Age-Related macular degeneration and diabetic macular edema: A review. Int J Mol Sci. 2022;23:9424. https:\/\/doi.org\/10.3390\/ijms23169424.","journal-title":"Int J Mol Sci"},{"key":"4651_CR16","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s40942-020-00250-z","volume":"6","author":"QD Nguyen","year":"2020","unstructured":"Nguyen QD, Heier JS, Do DV, Mirando AC, Pandey NB, Sheng H, et al. The Tie2 signaling pathway in retinal vascular diseases: a novel therapeutic target in the eye. Int J Retina Vitr. 2020;6:48. https:\/\/doi.org\/10.1186\/s40942-020-00250-z.","journal-title":"Int J Retina Vitr"},{"key":"4651_CR17","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.15252\/emmm.201505889","volume":"8","author":"JT Regula","year":"2016","unstructured":"Regula JT, Lundh von Leithner P, Foxton R, Barathi VA, Cheung CMG, Bo Tun SB, et al. Targeting key angiogenic pathways with a bispecific crossmab optimized for neovascular eye diseases. EMBO Mol Med. 2016;8:1265\u201388. https:\/\/doi.org\/10.15252\/emmm.201505889.","journal-title":"EMBO Mol Med"},{"key":"4651_CR18","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1016\/s0092-8674(00)81812-7","volume":"87","author":"S Davis","year":"1996","unstructured":"Davis S, Aldrich TH, Jones PF, Acheson A, Compton DL, Jain V, et al. Isolation of angiopoietin-1, a ligand for the TIE2 receptor, by secretion-trap expression cloning. Cell. 1996;87:1161\u20139. https:\/\/doi.org\/10.1016\/s0092-8674(00)81812-7.","journal-title":"Cell"},{"key":"4651_CR19","doi-asserted-by":"publisher","first-page":"a006550","DOI":"10.1101\/cshperspect.a006650","volume":"2","author":"G Thurston","year":"2012","unstructured":"Thurston G, Daly C. The complex role of angiopoietin-2 in the angiopoietin-tie signaling pathway. Cold Spring Harb Perspect Med. 2012;2:a006550. https:\/\/doi.org\/10.1101\/cshperspect.a006650.","journal-title":"Cold Spring Harb Perspect Med"},{"key":"4651_CR20","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1038\/s41433-020-01377-x","volume":"35","author":"AM Joussen","year":"2021","unstructured":"Joussen AM, Ricci F, Paris LP, Korn C, Quezada-Ruiz C, Zarbin M. Angiopoietin\/Tie2 signalling and its role in retinal and choroidal vascular diseases: a review of preclinical data. Eye Lond Engl. 2021;35:1305\u201316. https:\/\/doi.org\/10.1038\/s41433-020-01377-x.","journal-title":"Eye Lond Engl"},{"key":"4651_CR21","doi-asserted-by":"publisher","first-page":"3395","DOI":"10.2147\/DDDT.S368963","volume":"16","author":"AA Nair","year":"2022","unstructured":"Nair AA, Finn AP, Sternberg P. Spotlight on faricimab in the treatment of wet Age-Related macular degeneration: Design, development and place in therapy. Drug Des Devel Ther. 2022;16:3395\u2013400. https:\/\/doi.org\/10.2147\/DDDT.S368963.","journal-title":"Drug Des Devel Ther"},{"key":"4651_CR22","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1016\/S0140-6736(22)00010-1","volume":"399","author":"JS Heier","year":"2022","unstructured":"Heier JS, Khanani AM, Quezada Ruiz C, Basu K, Ferrone PJ, Brittain C, et al. Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials. Lancet Lond Engl. 2022;399:729\u201340. https:\/\/doi.org\/10.1016\/S0140-6736(22)00010-1.","journal-title":"Lancet Lond Engl"},{"key":"4651_CR23","doi-asserted-by":"publisher","first-page":"3747","DOI":"10.2147\/OPTH.S231801","volume":"15","author":"AM Khanani","year":"2021","unstructured":"Khanani AM, Russell MW, Aziz AA, Danzig CJ, Weng CY, Eichenbaum DA, et al. Angiopoietins as potential targets in management of retinal disease. Clin Ophthalmol Auckl NZ. 2021;15:3747\u201355. https:\/\/doi.org\/10.2147\/OPTH.S231801.","journal-title":"Clin Ophthalmol Auckl NZ"},{"key":"4651_CR24","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1007\/s40265-022-01713-3","volume":"82","author":"M Shirley","year":"2022","unstructured":"Shirley M, Faricimab. First Approval Drugs. 2022;82:825\u201330. https:\/\/doi.org\/10.1007\/s40265-022-01713-3.","journal-title":"First Approval Drugs"},{"key":"4651_CR25","unstructured":"Garraway L, Officer MDPD. Jan CM, Development head of GP. Genentech: News Features | FDA Approves Genentech\u2019s Bispecific Antibody For Two Leading Causes Of Vision Loss. https:\/\/www.gene.com\/media\/news-features\/fda-approves-genentech-s-bispecific-antibody-for-two-leading-causes-of-vision-loss. Accessed 9 2026."},{"key":"4651_CR26","unstructured":"European Commission approves Roche\u2019. s Vabysmo for treatment of retinal vein occlusion (RVO). https:\/\/www.roche.com\/\/media\/releases\/med-cor-2024-07-30. Accessed 9 Jan 2026."},{"key":"4651_CR27","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1016\/S0140-6736(22)00018-6","volume":"399","author":"CC Wykoff","year":"2022","unstructured":"Wykoff CC, Abreu F, Adamis AP, Basu K, Eichenbaum DA, Haskova Z, et al. Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials. Lancet Lond Engl. 2022;399:741\u201355. https:\/\/doi.org\/10.1016\/S0140-6736(22)00018-6.","journal-title":"Lancet Lond Engl"},{"key":"4651_CR28","doi-asserted-by":"publisher","first-page":"2797","DOI":"10.2147\/OPTH.S381503","volume":"16","author":"RB Rush","year":"2022","unstructured":"Rush RB, Rush SW. Faricimab for Treatment-Resistant diabetic macular edema. Clin Ophthalmol Auckl NZ. 2022;16:2797\u2013801. https:\/\/doi.org\/10.2147\/OPTH.S381503.","journal-title":"Clin Ophthalmol Auckl NZ"},{"key":"4651_CR29","doi-asserted-by":"publisher","first-page":"2397","DOI":"10.2147\/OPTH.S424314","volume":"17","author":"RB Rush","year":"2023","unstructured":"Rush RB. One year results of faricimab for Aflibercept-Resistant diabetic macular edema. Clin Ophthalmol Auckl NZ. 2023;17:2397\u2013403. https:\/\/doi.org\/10.2147\/OPTH.S424314.","journal-title":"Clin Ophthalmol Auckl NZ"},{"key":"4651_CR30","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.3390\/medicina59061125","volume":"59","author":"H Ohara","year":"2023","unstructured":"Ohara H, Harada Y, Hiyama T, Sadahide A, Minamoto A, Kiuchi Y. Faricimab for diabetic macular edema in patients refractory to Ranibizumab or Aflibercept. Med (Mex). 2023;59:1125. https:\/\/doi.org\/10.3390\/medicina59061125.","journal-title":"Med (Mex)"},{"key":"4651_CR31","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1159\/000438792","volume":"54","author":"F Bandello","year":"2015","unstructured":"Bandello F, Tejerina AN, Vujosevic S, Varano M, Egan C, Sivaprasad S, et al. Retinal layer location of increased retinal thickness in eyes with subclinical and clinical macular edema in diabetes type 2. Ophthalmic Res. 2015;54:112\u20137. https:\/\/doi.org\/10.1159\/000438792.","journal-title":"Ophthalmic Res"},{"key":"4651_CR32","doi-asserted-by":"publisher","first-page":"1089043","DOI":"10.1155\/2018\/1089043","volume":"2018","author":"L Rangaraju","year":"2018","unstructured":"Rangaraju L, Jiang X, McAnany JJ, Tan MR, Wanek J, Blair NP, et al. Association between visual acuity and retinal layer metrics in diabetics with and without macular edema. J Ophthalmol. 2018;2018:1089043. https:\/\/doi.org\/10.1155\/2018\/1089043.","journal-title":"J Ophthalmol"},{"key":"4651_CR33","doi-asserted-by":"publisher","first-page":"7585","DOI":"10.3390\/ijms23147585","volume":"23","author":"MR Munk","year":"2022","unstructured":"Munk MR, Somfai GM, de Smet MD, Donati G, Menke MN, Garweg JG, et al. The role of intravitreal corticosteroids in the treatment of DME: predictive OCT biomarkers. Int J Mol Sci. 2022;23:7585. https:\/\/doi.org\/10.3390\/ijms23147585.","journal-title":"Int J Mol Sci"},{"key":"4651_CR34","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1167\/iovs.64.13.31","volume":"64","author":"Y Takamura","year":"2023","unstructured":"Takamura Y, Yamada Y, Morioka M, Gozawa M, Matsumura T, Inatani M. Turnover of microaneurysms after intravitreal injections of faricimab for diabetic macular edema. Invest Ophthalmol Vis Sci. 2023;64:31. https:\/\/doi.org\/10.1167\/iovs.64.13.31.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"4651_CR35","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1167\/iovs.65.11.19","volume":"65","author":"A Ruffini","year":"2024","unstructured":"Ruffini A, Dvoriashyna M, Govetto A, Romano MR, Repetto R. A mathematical model of interstitial fluid flow and retinal tissue deformation in macular edema. Invest Ophthalmol Vis Sci. 2024;65:19. https:\/\/doi.org\/10.1167\/iovs.65.11.19.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"4651_CR36","doi-asserted-by":"publisher","first-page":"2156273","DOI":"10.1155\/2016\/2156273","volume":"2016","author":"P Romero-Aroca","year":"2016","unstructured":"Romero-Aroca P, Baget-Bernaldiz M, Pareja-Rios A, Lopez-Galvez M, Navarro-Gil R, Verges R. Diabetic macular edema pathophysiology: vasogenic versus inflammatory. J Diabetes Res. 2016;2016:2156273. https:\/\/doi.org\/10.1155\/2016\/2156273.","journal-title":"J Diabetes Res"},{"key":"4651_CR37","doi-asserted-by":"publisher","first-page":"2368","DOI":"10.1016\/j.ophtha.2016.07.010","volume":"123","author":"J Lee","year":"2016","unstructured":"Lee J, Moon BG, Cho AR, Yoon YH. Optical coherence tomography angiography of DME and its association with Anti-VEGF treatment response. Ophthalmology. 2016;123:2368\u201375. https:\/\/doi.org\/10.1016\/j.ophtha.2016.07.010.","journal-title":"Ophthalmology"},{"key":"4651_CR38","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1080\/09273948.2019.1704028","volume":"29","author":"A Dastiridou","year":"2021","unstructured":"Dastiridou A, Karathanou K, Riga P, Anagnostopoulou S, Balasubramanian S, Mataftsi A, et al. OCT angiography study of the macula in patients with diabetic macular edema treated with intravitreal Aflibercept. Ocul Immunol Inflamm. 2021;29:926\u201331. https:\/\/doi.org\/10.1080\/09273948.2019.1704028.","journal-title":"Ocul Immunol Inflamm"},{"key":"4651_CR39","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1016\/j.jcjo.2022.04.005","volume":"58","author":"V Kansal","year":"2023","unstructured":"Kansal V, Colleaux K, Rawlings N. OCTA changes following loading phase with intravitreal Aflibercept for DME. Can J Ophthalmol J Can Ophtalmol. 2023;58:480\u201390. https:\/\/doi.org\/10.1016\/j.jcjo.2022.04.005.","journal-title":"Can J Ophthalmol J Can Ophtalmol"},{"key":"4651_CR40","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1159\/000528426","volume":"246","author":"J-F Korobelnik","year":"2023","unstructured":"Korobelnik J-F, Gaucher D, Baillif S, Creuzot-Garcher C, Kodjikian L, Weber M. Optical coherence tomography angiography in diabetic macular edema treated with intravitreal aflibercept: A 48-Week observational study (the DOCTA study). Ophthalmol J Int Ophtalmol Int J Ophthalmol Z Augenheilkd. 2023;246:71\u201380. https:\/\/doi.org\/10.1159\/000528426.","journal-title":"Ophthalmol J Int Ophtalmol Int J Ophthalmol Z Augenheilkd"},{"key":"4651_CR41","doi-asserted-by":"publisher","first-page":"3579","DOI":"10.1007\/s10792-022-02374-7","volume":"42","author":"A Ceylan","year":"2022","unstructured":"Ceylan A, Dogan ME, Demircan A, Akar Y. Evaluation of macular vascular density and foveal avascular zone changes by optical coherence tomography angiography (OCT-A) after intravitreal dexamethasone implant in diabetic macular edema resistant to Anti-VEGF treatment. Int Ophthalmol. 2022;42:3579\u201388. https:\/\/doi.org\/10.1007\/s10792-022-02374-7.","journal-title":"Int Ophthalmol"}],"container-title":["BMC Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12886-026-04651-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12886-026-04651-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12886-026-04651-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T12:21:36Z","timestamp":1773145296000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12886-026-04651-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,6]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4651"],"URL":"https:\/\/doi.org\/10.1186\/s12886-026-04651-w","relation":{},"ISSN":["1471-2415"],"issn-type":[{"value":"1471-2415","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,6]]},"assertion":[{"value":"17 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study design was approved by the local ethics committee (Commission cantonale d\u2019\u00e9thique de la recherche sur l\u2019\u00eatre humain CER-VD -part of Swissethics) for data collection and analysis (BASEC 2023\u2009\u2212\u200900814; authorized on 28th Jun 2023) and was conducted in accordance with the Declaration of Helsinki. Informed consent to participate was obtained from all the participants in the study. Clinical trial number: not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Grant for medical writing - 2024.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"119"}}